(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

(177)Lu-PSMA radioligand therapy (LuPRLT) is mainly used for patients with metastatic castration-resistant prostate cancer who are resistant to established drugs. This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617, for 45 patients with predominant lymph node metastatic prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales: von Eyben, Finn Edler, Singh, Aviral, Zhang, Jingjing, Nipsch, Karin, Meyrick, Danielle, Lenzo, Nat, Kairemo, Kalevi, Joensuu, Timo, Virgolini, Irene, Soydal, Cigdem, Kulkarni, Harshad R., Baum, Richard Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497435/
https://www.ncbi.nlm.nih.gov/pubmed/31069008
http://dx.doi.org/10.18632/oncotarget.26789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497435/
https://www.ncbi.nlm.nih.gov/pubmed/31069008
http://dx.doi.org/10.18632/oncotarget.26789

Ejemplares similares